

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN: 0250-7005

Volume 36, Number 1, January 2016

Contents

Reviews

- Using Epigenetic Therapy to Overcome Chemotherapy Resistance. J. STRAUSS, W.D. FIGG (*Bethesda, MD, USA*) 1
- Potential of Amifostine for Chemoradiotherapy and Radiotherapy-associated Toxicity Reduction in Advanced NSCLC: A Meta-Analysis. A. DEVINE, L. MARIGNOL (*Dublin, Ireland*) 5
- Factors Affecting Survival in Patients with Lung Metastases from Colorectal Cancer. A Short Meta-analysis. F. LUMACHI, G.B. CHIARA, R. TOZZOLI, A. DEL CONTEA, S.M.M. BASSO (*Padova; Pordenone, Italy*) 13
- TAS-102 an Emerging Oral Fluoropyrimidine. J. CHEN, M. HAN, M.W. SAIF (*St. Lucia; Wollongong, Australia; Boston, MA, USA*) 21

Experimental Studies

- Inhibition of Chronic Pancreatitis and Murine Pancreatic Intraepithelial Neoplasia by a Dual Inhibitor of c-RAF and Soluble Epoxide Hydrolase in *LSL-Kras^{G12D}/Pdx-1-Cre* Mice. J. LIAO, S.H. HWANG, H. LI, J.-Y. LIU, B.D. HAMMOCK, G.-Y. YANG (*Chicago, IL; Davis, CA, USA*) 27
- HUHS1015 Suppresses Colonic Cancer Growth by Inducing Necrosis and Apoptosis in Association with Mitochondrial Damage. Y. KAKU, A. TSUCHIYA, T. SHIMIZU, A. TANAKA, T. NISHIZAKI (*Nishinomiya; Kobe, Japan*) 39
- A Novel Sirtuin-3 Inhibitor, LC-0296, Inhibits Cell Survival and Proliferation, and Promotes Apoptosis of Head and Neck Cancer Cells. T.Y. ALHAZZAZI, P. KAMARAJAN, Y. XU, T. AI, L. CHEN, E. VERDIN, Y.L. KAPILA (*Jeddah, Saudi Arabia; Ann Arbor, MI; Minneapolis, MN; San Francisco, CA, USA*) 49

Contents continued on the back cover

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment



ISSN (print): 0250-7005
ISSN (online): 1791-7530

Editorial Board

P. A. ABRAHAMSSON, Malmö, Sweden
B. B. AGGARWAL, Houston, TX, USA
T. AKIMOTO, Kashiwa, Chiba, Japan
P. Z. ANASTASIADIS, Jacksonville, FL, USA
A. ARGIRIS, San Antonio, TX, USA
J. P. ARMAND, Toulouse, France
V. I. AVRAMIS, Los Angeles, CA, USA
R. C. BAST, Houston, TX, USA
D.-T. BAU, Taichung, Taiwan, ROC
G. BAUER, Freiburg, Germany
E. E. BAULIEU, Le Kremlin-Bicetre, France
E. J. BENZ, Jr., Boston, MA, USA
J. BERGH, Stockholm, Sweden
F. T. BOSMAN, Lausanne, Switzerland
G. BROICH, Monza, Italy
Ø. S. BRULAND, Oslo, Norway
J. M. BUATTI, Iowa City, IA, USA
M. M. BURGER, Basel, Switzerland
M. CARBONE, Honolulu, HI, USA
C. CARLBERG, Kuopio, Finland
J. CARLSSON, Uppsala, Sweden
A. F. CHAMBERS, London, ON, Canada
P. CHANDRA, Frankfurt am Main, Germany
L. CHENG, Indianapolis, IN, USA
J.-G. CHUNG, Taichung, Taiwan, ROC
E. DE CLERCQ, Leuven, Belgium
W. DEN OTTER, Amsterdam, The Netherlands
E. P. DIAMANDIS, Toronto, ON, Canada
G. TH. DIAMANDOPOULOS, Boston, MA, USA
D. W. FELSHER, Stanford, CA, USA
J. A. FERNANDEZ-POL, Chesterfield, MO, USA
I. J. FIDLER, Houston, TX, USA
A. P. FIELDS, Jacksonville, FL, USA
B. FUCHS, Zurich, Switzerland
D. FUCHS, Innsbruck, Austria
G. GABBIANI, Geneva, Switzerland
R. GANAPATHI, Charlotte, NC, USA
A. F. GAZDAR, Dallas, TX, USA
J. H. GESCHWIND, Baltimore, MD, USA
A. GIORDANO, Philadelphia, PA, USA
G. GITSCH, Freiburg, Germany
R. H. GOLDFARB, Saranac Lake, NY, USA
L. HELSON, Quakertown, PA, USA
R. M. HOFFMAN, San Diego, CA, USA
S. C. JHANWAR, New York, NY, USA
J. V. JOHANNESSEN, Oslo, Norway
B. KAINA, Mainz, Germany
P. -L. KELLOKUMPU-LEHTINEN, Tampere, Finland
D. G. KIEBACK, Marl, Germany
R. KLAPDOR, Hamburg, Germany
S. D. KOTTARIDIS, Athens, Greece
G. R. F. KRUEGER, Köln, Germany
Pat M. KUMAR, Manchester, UK

Shant KUMAR, Manchester, UK
O. D. LAERUM, Bergen, Norway
F. J. LEJEUNE, Lausanne, Switzerland
L. F. LIU, Piscataway, NJ, USA
D. M. LOPEZ, Miami, FL, USA
E. LUNDGREN, Umeå, Sweden
Y. MAEHARA, Fukuoka, Japan
J. MAHER, London, UK
J. MARESCAUX, Strasbourg, France
J. MARK, Skövde, Sweden
S. S. MARTIN, Baltimore, MD, USA
S. MITRA, Houston, TX, USA
S. MIYAMOTO, Fukuoka, Japan
M. MUELLER, Villingen-Schwenningen, Germany
F. M. MUGGIA, New York, NY, USA
M. NAMIKI, Kanazawa, Ishikawa, Japan
R. NARAYANAN, Boca Raton, FL, USA
K. NILSSON, Uppsala, Sweden
S. PATHAK, Houston, TX, USA
J.L. PERSSON, Malmö, Sweden
G. J. PILKINGTON, Portsmouth, UK
C. D. PLATSOUKAS, Norfolk, VA, USA
A. POLLIACK, Jerusalem, Israel
M. RIGAUD, Limoges, France
U. RINGBORG, Stockholm, Sweden
M. ROSELLI, Rome, Italy
A. SCHAUER, Göttingen, Germany
M. SCHNEIDER, Wuppertal, Germany
A. SETH, Toronto, ON, Canada
G. V. SHERBET, Newcastle-upon-Tyne, UK
G.-I. SOMA, Kagawa, Japan
G. S. STEIN, Burlington, VT, USA
T. STIGBRAND, Umeå, Sweden
T. M. THEOPHANIDES, Athens, Greece
P. M. UELAND, Bergen, Norway
H. VAN VLIERBERGHE, Ghent, Belgium
R. G. VILE, Rochester, MN, USA
M. WELLER, Zurich, Switzerland
B. WESTERMARK, Uppsala, Sweden
Y. YEN, Duarte, CA, USA
M.R.I. YOUNG, Charleston, SC, USA
B. ZUMOFF, New York, NY, USA

J. G. DELINASIOS, Athens, Greece
Managing Editor

G. J. DELINASIOS, Athens, Greece
Assistant Managing Editor and
Executive Publisher

E. ILIADIS, Athens, Greece
Production Editor

Editorial Office: International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece. Tel / Fax: +30-22950-53389.

U.S. Branch: Anticancer Research USA, Inc., 111 Bay Avenue, Highlands, NJ 07732, USA.

E-mails: Editorial Office: journals@iia-anticancer.org

Managing Editor: editor@iia-anticancer.org

ANTICANCER RESEARCH supports: (a) the establishment and the activities of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR; Kapandriti, Attiki, Greece); and (b) the organization of the International Conferences of Anticancer Research. The IIAR is a member of UICC. For more information about ANTICANCER RESEARCH, IIAR and the Conferences, please visit the IIAR website: www.iia-anticancer.org

Publication Data: ANTICANCER RESEARCH (AR) is published monthly from January 2009. Each annual volume comprises 12 issues. Annual Author and Subject Indices are included in the last issue of each volume. ANTICANCER RESEARCH Vol. 24 (2004) and onwards appears online with Stanford University HighWire Press from April 2009.

Copyright: On publication of a manuscript in AR, which is a copyrighted publication, the legal ownership of all published parts of the paper passes from the Author(s) to the Journal.

Annual Subscription Rates 2016 per volume: Institutional subscription US\$ 1,898.00 (online) or US\$ 2,277.00 (print & online). Personal subscription US\$ 897.00 (online) or US\$ 1,277.00 (print & online). Prices include rapid delivery and insurance. The complete previous volumes of Anticancer Research (Vol. 1-35, 1981-2015) are available at 50% discount on the above rates.

Subscription Orders: Orders can be placed at agencies, bookstores, or directly with the Publisher. (e-mail: subscriptions@iia-anticancer.org)

Advertising: All correspondence and rate requests should be addressed to the Editorial Office.

Book Reviews: Recently published books and journals should be sent to the Editorial Office. Reviews will be published within 2-4 months.

Articles in ANTICANCER RESEARCH are regularly indexed in all bibliographic services, including Current Contents (Life Sciences), Science Citation Index, Index Medicus, Biological Abstracts, PubMed, Chemical Abstracts, Excerpta Medica, University of Sheffield Biomedical Information Service, Current Clinical Cancer, AIDS Abstracts, Elsevier Bibliographic Database, EMBASE, Compendex, GEOBASE, EMBiology, Elsevier BIOBASE, FLUIDEX, World Textiles, Scopus, Progress in Palliative Care, Cambridge Scientific Abstracts, Cancergram (International Cancer Research Data Bank), MEDLINE, Reference Update - RIS Inc., PASCAL-CNRS, Inpharma-Reactions (Datastar, BRS), CABS, Immunology Abstracts, Telegen Abstracts, Genetics Abstracts, Nutrition Research Newsletter, Dairy Science Abstracts, Current Titles in Dentistry, Inpharma Weekly, BioBase, MedBase, CAB Abstracts/Global Health Databases, Investigational Drugs Database, VINITI Abstracts Journal, Leeds Medical Information, PubsHub, Sociedad Iberoamericana de Información Científica (SIIC) Data Bases.

Authorization to photocopy items for internal or personal use, or the internal or personal clients, is granted by ANTICANCER RESEARCH, provided that the base fee of \$2.00 per copy, plus 0.40 per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 0250-7005/2016 \$2.00 +0.40.

The Editors and Publishers of ANTICANCER RESEARCH accept no responsibility for the opinions expressed by the contributors or for the content of advertisements appearing therein.

Copyright© 2016, International Institute of Anticancer Research (Dr. John G. Delinasios), All rights reserved.

D.T.P. BY IIAR

PRINTED BY ENTYP0, ATHENS, GREECE. PRINTED ON ACID-FREE PAPER

ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment
ISSN (print): 0250-7005, ISSN (online): 1791-7530

VOLUME 36
2016

Editorial Board

P.A. Abrahamsson	Department of Urology, Skåne University Hospital, Lund University, Malmö, Sweden
B. B. Aggarwal	Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
T. Akimoto	Division of Particle Therapy and Department of Radiation Oncology, National Cancer Center East, Kashiwa, Chiba, Japan
P. Z. Anastasiadis	Department of Cancer Biology, Mayo Cancer Center, Jacksonville, FL, USA
A. Argiris	Division of Hematology/Oncology, UT Health Science Center at San Antonio, San Antonio, TX, USA
J. P. Armand	Institut Claudius Regaud, Toulouse, France
V. I. Avramis	Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA
D.-T. Bau	Terry Fox Cancer Research Lab, China Medical University Hospital, Taichung, Taiwan, ROC
G. Bauer	Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany
E. E. Baulieu	INSERM U488 and College de France, Le Kremlin-Bicetre, France
E. J. Benz, Jr.	Dana-Farber Cancer Institute, Boston, MA, USA
J. Bergh	Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden
F. T. Bosman	Institute of Pathology, University of Lausanne, Switzerland
G. Broich	Gruppo Policlinico di Monza, Monza, Italy
Ø. S. Bruland	Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway
J. M. Buatti	Department of Radiation Oncology, University of Iowa, Iowa City, IA, USA
M. M. Burger	Novartis, Basel, Switzerland
M. Carbone	Cancer Research Center of Hawaii, Honolulu, HI, USA
C. Carlberg	Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
J. Carlsson	Department of Biomedical Radiation Sciences, Uppsala University, Sweden
A. F. Chambers	Department of Oncology, London Regional Cancer Center, London, Ontario, Canada
P. Chandra	Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany
L. Cheng	Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA
J.-G. Chung	Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC
E. De Clercq	Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
W. Den Otter	VUMC, Department of Urology, Amsterdam, The Netherlands
E. P. Diamandis	Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada
G. Th. Diamandopoulos	Department of Pathology, Harvard Medical School, Boston, MA, USA
D.W. Felsner	Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA
J. A. Fernandez-Pol	Metalloproteomics, LLC, Chesterfield, MO, USA
I. J. Fidler	Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
A.P. Fields	Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA
B. Fuchs	Balgrist University Hospital, Zurich, Switzerland
D. Fuchs	Center for Chemistry and Biomedicine, Innsbruck Medical University, Innsbruck, Austria
G. Gabbiani	Department of Pathology, University of Geneva, Switzerland
R. Ganapathi	Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC, USA
A. F. Gazdar	Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA
J.H. Geschwind	Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
A. Giordano	Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA
G. Gitsch	Department of Gynecology and Obstetrics, University of Freiburg, Germany
R. H. Goldfarb	Trudeau Institute, Saranac Lake, NY, USA

L. Helson	Sign Path Pharma, Inc., Quakertown, PA, USA
R. M. Hoffman	Department of Surgery, University of California, San Diego, CA, USA
S. C. Jhanwar	Laboratory of Solid Tumor Genetics, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
J. V. Johannessen	Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway
B. Kaina	Institute of Toxicology, University of Mainz, Germany
P. -L. Kellokumpu-Lehtinen	Department of Oncology and Radiotherapy, Tampere University Hospital, Tampere, Finland
D. G. Kieback	Klinikum Vest, Standort Marl, Marl, Germany
R. Klapdor	Medical Clinic, University of Hamburg, Germany
S. D. Kottaridis	Department of Virology, Hellenic Anticancer Institute, Athens, Greece
G. R. F. Krueger	Center of Anatomy II, University of Cologne Medical School, Cologne, Germany
Pat M. Kumar	Department of Biological Sciences, Manchester Metropolitan University, Manchester, UK
Shant Kumar	Department Pathology, University of Manchester Medical School, Manchester, UK
O. D. Laerum	Department of Pathology, The Gade Institute, University of Bergen, Norway
F. J. Lejeune	Fondation du Centre Pluridisciplinaire d' Oncologie, CHUV, Lausanne, Switzerland
L. F. Liu	Department of Pharmacology, UMD of New Jersey, Piscataway, NJ, USA
D. M. Lopez	Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL, USA
E. Lundgren	Unit of Applied Cell and Molecular Biology, University of Umeå, Sweden
Y. Maehara	Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
J. Maher	Department of Research Oncology, Division of Cancer Studies, King's College London School of Medicine, Guy's Hospital Campus, London, UK
J. Marescaux	IRCAD, University of Strasbourg, France
J. Mark	Department of Pathology, Kärnshjukhuset, Skövde, Sweden
S. S. Martin	Department of Physiology, University of Maryland School of Medicine, Baltimore, MD, USA
S. Mitra	The Methodist Hospital Research Institute (TMHRI), Houston, TX, USA
S. Miyamoto	Department of Obstetrics and Gynecology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
M. Mueller	Hochschule Furtwangen University, Villingen-Schwenningen, Germany
F. M. Muggia	New York University Cancer Institute, School of Medicine, NY, USA
M. Namiki	Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa City, Ishikawa, Japan
R. Narayanan	Department of Biological Sciences, Florida Atlantic University, Boca Raton, FL, USA
K. Nilsson	Rudbeck Laboratory, Department of Genetics and Pathology, Uppsala University Hospital, Sweden
S. Pathak	Department of Cell Biology, University of Texas, Houston, TX, USA
J.L. Persson	Section for Experimental Cancer Research, Clinical Research Center, Lund University, Malmö, Sweden
G. J. Pilkington	Department of Cellular and Molecules Neurooncology, School of Pharmacy and Biomedical Sciences, University of Portsmouth, UK
C. D. Platsoucas	College of Sciences, Old Dominion University, Norfolk, VA, USA
A. Polliack	Department of Haematology, Hadassah University Hospital and Medical School, Jerusalem, Israel
M. Rigaud	Laboratory Biochimie et Génétique Molecules, Faculté de Médecine de Limoges, France
U. Ringborg	Department of General Oncology, Karolinska Hospital, Stockholm, Sweden
M. Roselli	Department of Medical Oncology, University of Rome "Tor Vergata", Italy
A. Schauer	Zentrum Pathologie, Georg-August Universität, Göttingen, Germany
M. Schneider	Department of Organic Chemistry, Bergische University, Wuppertal, Germany
A. Seth	Laboratory of Molecular Pathology, Sunnybrook Research Institute and University of Toronto, Ontario, Canada
G. V. Sherbet	Cancer Research Unit, University of Newcastle-upon-Tyne, UK

G.-I. Soma	Department of Integrated and Holistic Immunology, Faculty of Medicine, Kagawa University, Kagawa, Japan
G. S. Stein	Department of Biochemistry, College of Medicine, University of Vermont, Burlington, VT, USA
T. Stigbrand	Department of Immunology, Umeå University, Umeå, Sweden
T. M. Theophanides	Department of Chemistry, Technical University of Athens, Greece
P. M. Ueland	Clinical Pharmacology Unit, Department of Pharmacology, University of Bergen, Norway
H. Van Vlierberghe	Department of Gastroenterology and Hepatology, Ghent University Hospital, Ghent, Belgium
R.G. Vile	Department of Immunology, Mayo Clinic, Rochester, MN, USA
M. Weller	Department of Neurology, University Hospital Zurich, Zurich, Switzerland
B. Westermark	Rudbecklaboratoriet, Department of Genetics and Pathology, University of Uppsala, Sweden
Y. Yen	Department of Molecular Pharmacology, City of Hope, Duarte, CA, USA
M.R.I. Young	Ralph H. Johnson VA Medical Center, Medical University of South Carolina, Charleston, SC, USA
B. Zumoff	Division of Endocrinology and Metabolism, Beth Israel Medical Center, New York, NY, USA

Instructions for Authors 2016

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear inline in the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

Tables. All tables should appear inline in the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts", "Index Medicus", "Merck Index", "IUPAC –IUB", "Bergey's Manual of Determinative Bacteriology", The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references.

Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html>

In case a submission is incomplete, the corresponding Author will be notified accordingly.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles published in 2015 are entitled to a complimentary online subscription to Anticancer Research 2015. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Copyright© 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click [here](#))
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal's secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions to authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.

(Rejection rate (2014): 65%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Reviews